Dr. Pasche has served as president and Chief Executive Officer of the Barbara Ann Karmanos Cancer Institute and chair of the Department of Oncology at Wayne State University since 2023. Before joining Karmanos, he served as director of the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC), principal investigator of the NCI CCSG award, and chair of the Department of Cancer Biology from 2014 until 2022. He was the first to identify and characterize TGFBR1*6A, an in-frame deletion within TGFBR1 exon 1, which has emerged as a low penetrance tumor susceptibility allele. Dr. Pasche is the co-inventor and principal developer of a novel medical device delivering amplitude-modulated radiofrequency electromagnetic fields for systemic targeted cancer treatment. The device is FDA-approved for the treatment of patients with advanced hepatocellular carcinoma who fail first- and second-line therapy.
A native of Switzerland, Dr. Pasche earned his doctorate of medicine and doctorate of philosophy from the Karolinska Institute in Stockholm, Sweden, and another doctorate of medicine from the University of Lausanne in Switzerland. Following a postdoctoral fellowship at the Brigham and Women’s Hospital, Harvard Medical School, Dr. Pasche completed an internship and residency in internal medicine at the New York Hospital at Cornell University Medical Center. He also went on to complete a hematology and oncology fellowship at Memorial Sloan-Kettering Cancer Center and a second postdoctoral fellowship at Howard Hughes Medical Institute and Sloan-Kettering Institute for Cancer Research
The Barbara Ann Karmanos Cancer Institute has been awarded $459,010 for continued research in treating cancers with radiofrequency electromagnetic fields. Leaders from U CAN-CER VIVE Foundation, an organization that supports cancer research in Michigan, delivered the check to Karmanos researchers in March. U CAN-CER VIVE was co-founded by Ryan and Kelley LaFontaine. The funds will help open clinical trial studies in cancer treatment of breast, colorectal and pancreatic cancers, and continue studies in l...
Castle Connolly’s 2025 Top Doctors list has been announced, with 18 Barbara Ann Karmanos Cancer Institute physicians listed. There are about 1 million practicing physicians in the U.S. Castle Connolly’s list includes over 70,000 physicians, the top 7% of physicians across the country, all board-certified in 85 medical specialties. Selection for the Top Doctors list is based on peer nominations (over 39,000 nominations were submitted in 2024), professional achievements, and excellence in patient care. A ...
The Barbara Ann Karmanos Cancer Institute , the largest provider of cancer care and research in Michigan and part of McLaren Health Care, announced today that the new TheraBionic P1 device, an FDA-approved, at-home treatment , is now available to treat advanced liver cancer. Karmanos Cancer Center is the first institution worldwide to prescribe this treatment. The TheraBionic P1 device is a novel, handheld, portable device that produces low levels of 27.12 MHz radiofrequency electromagnetic fields, whic...